Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma

Background: Despite advances in therapeutics, outcomes for hepatocellular carcinoma (HCC) remain poor and there is an urgent need for efficacious systemic therapy. Unfortunately, drugs that are successful in preclinical studies often fail in the clinical setting, and we hypothesize that this is due to functional differences between primary tumors and commonly used preclinical models. In this study, we attempt to answer this question by comparing tumor morphology and gene expression profiles between primary tumors, xenografts and HCC cell lines.

30

Wang W, Iyer NG, Tay HT, Wu Y, Lim TK, Zheng L, Song IC, Kwoh CK, Huynh H, Tan PO, Chow PK